Announcement of voluntary disclosure of clinical trial approval notice for drug clinical trial of HP560 tablets used for the treatment of myelofibrosis (myeloproliferative tumor)
Announcement of voluntary disclosure of the clinical phase I/II trial application for HP537 for the treatment of hematological malignancies approved by the United States FDA.
Announcement on voluntary disclosure of oral PROTAC drug HP518 intended for the treatment of androgen receptor (AR) positive triple-negative breast cancer granted Fast Track designation by the US FDA.
Investor Relations Activity Record Form of Haichuang Pharmaceutical (June 17-26, 2024)
Announcement on the plan of concentrated bidding reduction of shareholding by shareholders holding more than 5% of the shares
Announcement on voluntary disclosure of clinical data for the PROTAC drug under development HP518 to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Announcement on the resignation of senior management personnel and adjustment of core technical personnel
CITIC Securities Co., Ltd.'s inspection opinion on the departure of core technicians of Haichuang Pharmaceutical Co., Ltd.
Haichuang Pharmaceutical Investor Relations Activity Record Form (May 15 to May 21, 2024)
Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Group Performance Briefing and the First Quarter 2024 Results Briefing
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Legal Opinion of Beijing Junhe (Chengdu) Law Firm on the 2023 Annual General Meeting of Shareholders of Haichuang Pharmaceutical Co., Ltd.
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Haichuang Pharmaceutical Co., Ltd.
2023 Annual General Meeting of Shareholders Meeting Materials
2024 First Quarter Report
CITIC Securities Co., Ltd.'s 2023 Continuous Supervision Site Inspection Report on Haichuang Pharmaceutical Co., Ltd.
Report on the work of the Board of Supervisors for the year 2023
Announcement on the company's 2024 related transaction forecast
Special report on the storage and actual use of funds raised in 2023
Announcement on adjustments to some initial public offering of shares
No Data